Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
- Citation:
- Future Oncol vol 17 (34) 4665-4676
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Accepted
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 3537
- Children:
- None
- Pharmas:
- Seagan
- Grants:
- U10CA180821, U10CA180882, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233373, UG1CA232760
- Corr. Author:
- Authors:
- Ciara C O'Sullivan Karla V Ballman Linda McCall Anuhya Kommalapati Tyler Zemla Anna Weiss Melissa Mitchell Victoria Blinder Nadine M Tung William J Irvin Myounghee Lee Matthew P Goetz William Fraser Symmans Virginia F Borges Ian Krop Lisa A Carey Ann H Partridge
- Networks:
- LAPS-CO070, LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, MD015, NY167, PCRC, SCOR
- Study
- Alliance-A011801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- HER2-positive early breast cancer, postneoadjuvant, residual disease, T-DM1, tucatinib